指南与共识其他结缔组织病

IMACS指南癌症风险分层在特发性炎性肌病中的真实世界应用

Real-world application of the international myositis assessment and clinical studies group guidelines on cancer risk stratification.
指南 / 共识 · Rheumatology (Oxford) · 2026-01-01

该多中心回顾性研究纳入意大利5个风湿病中心的411例特发性炎性肌病(IIM)患者,按2023年IMACS指南分为标准、中危和高危组,评估3年内癌症发生及筛查依从性。高危组癌症风险显著升高(OR=4.05,P=0.026),抗TIF1γ和抗SAE1为独立预测因子,但中危组强化筛查不足且筛查依从性随时间下降。

要点

  • IMACS分层可有效预测IIM患者3年内癌症风险,高危组OR为4.05。
  • 抗TIF1γ(OR=12.3)和抗SAE1(OR=11.9)是癌症独立预测因子。
  • 真实世界中危组强化筛查不足,筛查依从性随时间下降。

核心结论

  • IMACS风险分层模型能有效预测IIM患者的癌症风险。
  • 真实世界筛查实践与指南推荐存在不一致,尤其在中危患者中强化筛查使用不足。

研究设计与样本

  • 多中心回顾性研究,纳入意大利5个风湿病中心的411例IIM患者。
  • 按IMACS指南分为标准、中危和高危组,评估IIM诊断后3年内癌症发生。
  • 比较IMACS指南实施前的筛查实践与指南推荐,采用逻辑回归分析分层预测价值。

主要发现

  • 411例中高危180例(43.8%)、中危156例(37.7%)、标准危75例(18.2%)。
  • 9.2%的患者在IIM起病3年内诊断癌症,高危组发生恶性肿瘤的OR=4.05(P=0.026)。
  • 抗TIF1γ(OR=12.3,P<0.001)和抗SAE1(OR=11.9,P=0.012)为癌症独立预测因子。
  • 筛查依从性不一,中危组强化筛查使用不足,且筛查随时间下降。

关键数值与推荐

  • IMACS指南将IIM患者分为标准、中危和高危三层进行癌症筛查风险分层。
  • 高危组3年内癌症风险显著高于其他组(OR=4.05,P=0.026)。

临床怎么用

  • 对IIM患者应依据IMACS分层进行风险适应性癌症筛查,高危组尤其需加强监测。
  • 抗TIF1γ和抗SAE1阳性患者应视为癌症高风险,需强化筛查。
  • 中危患者强化筛查不足,临床需关注并提高该组筛查依从性。

局限性

  • 回顾性研究设计可能影响筛查实践数据的完整性。
  • 筛查实践比较基于IMACS指南实施前,存在时间偏倚可能。
  • 样本来自意大利多中心,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The 2023 International Myositis Assessment and Clinical Studies Group (IMACS) guidelines introduced a standardized risk-stratification model for cancer screening in idiopathic inflammatory myopathies (IIM). However, real-world data on their application remain limited. This study aimed to evaluate the effectiveness of IMACS-based risk stratification in predicting malignancy and assess adherence to cancer screening recommendations in a multicentric Italian IIM cohort. METHODS: We conducted a multicentre retrospective study including 411 IIM patients from five Italian rheumatology centres, classified into IMACS-defined standard, intermediate and high-risk groups. Cancer occurrence within three years of IIM diagnosis was assessed. Screening practices prior to the implementation of IMACS guidelines were compared with their recommendations. Logistic regression analysis was used to evaluate the predictive value of IMACS stratification. RESULTS: Among 411 patients, 180 (43.8%) were classified as high-risk, 156 (37.7%) as intermediate-risk and 75 (18.2%) as standard-risk. Cancer was diagnosed in 9.2% of patients within three years of IIM onset, with high-risk patients significantly more likely to develop malignancy (OR = 4.05, P = 0.026). Anti-TIF1γ (OR = 12.3, P < 0.001) and anti-SAE1 (OR = 11.9, P = 0.012) were independent predictors of cancer. Screening adherence varied, with underutilization of enhanced screening in intermediate-risk patients and a decline in screening over time. CONCLUSION: The IMACS stratification model effectively predicts cancer risk in IIM. However, real-world screening practices show inconsistencies, particularly in intermediate-risk patients. These findings support the need for optimized, risk-adapted malignancy surveillance in IIM and refinement of current guidelines based on real-world data.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pellico MR, Bochicchio C, Iannone C, et al. Real-world application of the international myositis assessment and clinical studies group guidelines on cancer risk stratification. Rheumatology (Oxford). 2026. PMID: 41936078. doi:10.1093/rheumatology/keag171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。